High vs Low Dose Dexamethasone on Complications in the Immediate Postoperative Phase After Nephrectomy (DEX-NEF)
Primary Purpose
Kidney Diseases, Postoperative Complications
Status
Terminated
Phase
Phase 4
Locations
Denmark
Study Type
Interventional
Intervention
Dexamethasone
Sponsored by
About this trial
This is an interventional treatment trial for Kidney Diseases
Eligibility Criteria
Inclusion Criteria:
Planned open kidney resection, heminephrectomy, nephrectomy Signed informed consent
Exclusion Criteria:
- chronic/ongoing use of glucocorticoids (except inhalation therapy)
- ongoing use of immunosuppressive therapy
- insulin dependent diabetes
- pregnancy/breastfeeding
- allergies toward study medication, or medication in a standard treatment
- previous kidney resection on same side
- thrombectomy in vena cava above diaphragma
- surgery cannot be performed
Sites / Locations
- Rigshospitalet
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
High dose
Low dose
Arm Description
Dexamethasone 24 mg
Dexamethasone 8 mg
Outcomes
Primary Outcome Measures
Post-operative complications
Complications requiring treatment in the PACU
Secondary Outcome Measures
Length of stay, PACU
Total length of stay in PACU
Length of stay, hospital
Total length of stay in hospital
Discharge score
Discharge score (according to discharge criteria) in the operating theater
Discharge score
Discharge score (according to discharge criteria) in the PACU
Complications
Complications requiring treatment in the ward
Pain postoperative
Self-reported pain (worst and average, days 0-4). Questionnaire.
Analgesics
Self-reported use of pain medication other than standard treatment (days 0-4). Questionnaire.
Post operative nausea and vomiting (PONV)
Self-reported ponv (worst and average, days 0-4. Questionnaire.
Antiemetics
Use of antiemetics other than standard treatment (days 0-4. Questionnaire.
Sleep
Self-reported quality of sleep (days 0-4). Questionnaire.
Mental status
Self-reported feelings of anxiety, unrest, sadness (days 0-4). Questionnaire.
Wound complications
Wound complications/infections
Readmissions
Any readmissions
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT03160729
Brief Title
High vs Low Dose Dexamethasone on Complications in the Immediate Postoperative Phase After Nephrectomy
Acronym
DEX-NEF
Official Title
High vs Low Dose Dexamethasone on Complications in the Immediate Postoperative Phase After Nephrectomy (DEX-NEF)
Study Type
Interventional
2. Study Status
Record Verification Date
January 2019
Overall Recruitment Status
Terminated
Why Stopped
Slow recruitment, schanges in standard treatment
Study Start Date
April 24, 2017 (Actual)
Primary Completion Date
November 23, 2018 (Actual)
Study Completion Date
November 23, 2018 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Rigshospitalet, Denmark
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The aim of this study is to investigate the effect of a single preoperative high-dose steroid injection on complications in the immediate postoperative phase after open kidney surgery (kidney resection, heminephrectomy, nephrectomy). Primary outcome is complications in the post anaesthesia care unit (PACU). Secondary outcomes are organospecific complications in the post anaesthesia phase, pain and nausea the first 5 days, seroma and wound infection the first 14 days and readmissions the first 30 days after surgery.
The investigators hypothesize that the frequency of transfer to the PACU and organospecific complications will be lower among patients receiving high dose dexamethasone. The investigators hypothesize, that there will be no difference in wound infections, seroma or readmissions.
Detailed Description
Post-surgery, patients are traditionally observed and treated in post-anesthesia care units (PACU) until they are discharged to the ward (or directly home) assessed by standardized international discharge criteria.
The research project "Why in PACU?" (Rigshospitalet, Denmark), has since the beginning of 2016 systematically collected and analyzed procedure-related complications in the recovery phase. The complications include pain, nausea/vomiting, circulatory and respiratory problems, orthostatic intolerance and cognitive disorders. Common to all the above-mentioned post-operative problems are the possible links to the inflammatory response caused by the surgical trauma.
Glucocorticoids can in this context be central for the reduction of acute postoperative organ dysfunctions, caused by the anti-inflammatory effect. In a number of different surgical procedures, single dose, pre-operative glucocorticoids have been shown to reduce post-operative nausea and vomiting (PONV), acute pain and need of opioids as well as accelerate the convalescence.
Meta-analyses also showed that single-dose administration of glucocorticoids (methylprednisolone and dexamethasone) for surgical patients is safe as opposed to long-term treatment.
The "Why in PACU?" database shows that 60 % of patients having open kidney surgery have complications in the PACU (primarily pain and hypoxia).
Based on positive results in other procedure-specific studies, all donor-nephrectomy patients at Rigshospitalet, have received pre-operative high-dose steroids, in the form of 24 mg dexamethasone injection since mid-2015. This has resulted in a reduction of pain requiring treatment with 30 %.
Prior to creating clinical recommendations and standards, it is required that the results be tested in a randomized, controlled, clinical trial.
The study is not placebo-controlled since the positive effects of dexamethasone 8 mg on PONV have been shown in numerous trials, and is already being administered to all patients at the clinic. It would therefore not be ethically correct to withdraw from this practise
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Kidney Diseases, Postoperative Complications
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
45 (Actual)
8. Arms, Groups, and Interventions
Arm Title
High dose
Arm Type
Active Comparator
Arm Description
Dexamethasone 24 mg
Arm Title
Low dose
Arm Type
Active Comparator
Arm Description
Dexamethasone 8 mg
Intervention Type
Drug
Intervention Name(s)
Dexamethasone
Intervention Description
pre-operative, single-shot injection
Primary Outcome Measure Information:
Title
Post-operative complications
Description
Complications requiring treatment in the PACU
Time Frame
24 hours
Secondary Outcome Measure Information:
Title
Length of stay, PACU
Description
Total length of stay in PACU
Time Frame
24 hours
Title
Length of stay, hospital
Description
Total length of stay in hospital
Time Frame
1 month
Title
Discharge score
Description
Discharge score (according to discharge criteria) in the operating theater
Time Frame
1 hour
Title
Discharge score
Description
Discharge score (according to discharge criteria) in the PACU
Time Frame
24 hours
Title
Complications
Description
Complications requiring treatment in the ward
Time Frame
24 hours
Title
Pain postoperative
Description
Self-reported pain (worst and average, days 0-4). Questionnaire.
Time Frame
4 days
Title
Analgesics
Description
Self-reported use of pain medication other than standard treatment (days 0-4). Questionnaire.
Time Frame
4 days
Title
Post operative nausea and vomiting (PONV)
Description
Self-reported ponv (worst and average, days 0-4. Questionnaire.
Time Frame
4 days
Title
Antiemetics
Description
Use of antiemetics other than standard treatment (days 0-4. Questionnaire.
Time Frame
4 days
Title
Sleep
Description
Self-reported quality of sleep (days 0-4). Questionnaire.
Time Frame
4 days
Title
Mental status
Description
Self-reported feelings of anxiety, unrest, sadness (days 0-4). Questionnaire.
Time Frame
4 days
Title
Wound complications
Description
Wound complications/infections
Time Frame
30 days
Title
Readmissions
Description
Any readmissions
Time Frame
30 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Planned open kidney resection, heminephrectomy, nephrectomy Signed informed consent
Exclusion Criteria:
chronic/ongoing use of glucocorticoids (except inhalation therapy)
ongoing use of immunosuppressive therapy
insulin dependent diabetes
pregnancy/breastfeeding
allergies toward study medication, or medication in a standard treatment
previous kidney resection on same side
thrombectomy in vena cava above diaphragma
surgery cannot be performed
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kristin J Steinthorsdottir, MD
Organizational Affiliation
Rigshospitalet, Denmark
Official's Role
Principal Investigator
Facility Information:
Facility Name
Rigshospitalet
City
Copenhagen
ZIP/Postal Code
2100
Country
Denmark
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
High vs Low Dose Dexamethasone on Complications in the Immediate Postoperative Phase After Nephrectomy
We'll reach out to this number within 24 hrs